Red blood cells function as reservoirs of tumor DNA
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Red blood cells (RBCs) can capture tumor DNA, offering a novel method for early lung cancer detection. This discovery overcomes limitations of cell-free DNA (ctDNA) analysis for biopsy-free cancer diagnostics.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Novel screening techniques for early lung cancer detection are crucial.
- Circulating tumor cell-free DNA (ctDNA) shows promise for biopsy-free tumor genotyping but faces sensitivity limitations due to scarcity and short half-life.
- Red blood cells (RBCs) sequester mitochondrial DNA, representing an unrecognized reservoir for circulating nucleic acids.
Purpose Of The Study
- To investigate RBCs as a potential reservoir for tumor DNA.
- To explore the utility of RBC-bound tumor DNA for early non-small cell lung cancer (NSCLC) detection.
- To establish a novel, biopsy-free approach for lung cancer diagnostics.
Main Methods
- Co-culturing lung cancer cell lines (with KRAS and EGFR mutations) with RBCs.
- Detecting RBC-bound tumor DNA using quantitative polymerase chain reaction (qPCR).
- Comparing RBC-bound tumor DNA levels in early-stage NSCLC patients and healthy controls.
Main Results
- RBCs acquired tumor DNA from lung cancer cell lines harboring KRAS and EGFR mutations.
- RBC-bound tumor DNA was detectable in patients with early-stage NSCLC.
- RBC-bound tumor DNA was not detected in healthy controls.
Conclusions
- RBCs serve as a previously unrecognized reservoir for tumor DNA.
- RBC-bound tumor DNA detection offers a promising, biopsy-free method for early lung cancer diagnostics.
- This approach enhances the sensitivity and clinical utility of noninvasive cancer detection methods.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...